Form 4: Candel Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, sold 22,081 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Francesca Barone, the Chief Scientific Officer of Candel Therapeutics, sold 22,081 shares of common stock on November 29, 2024.
• The sale was executed at a price of $4.5556 per share.
• This transaction was not a discretionary sale but was required to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Ms. Barone directly owns 137,880 shares of Candel Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate a change in the company's outlook or strategy.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies have mandatory sell-to-cover policies similar to Candel Therapeutics.

Stakeholder Impact

• The sale has a minor impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Candel Therapeutics, insider trading, stock sale, Form 4, Francesca Barone, restricted stock units, tax obligations